CR20140298A - Nuevo uso terapéutico de antagonistas del receptor p75 - Google Patents
Nuevo uso terapéutico de antagonistas del receptor p75Info
- Publication number
- CR20140298A CR20140298A CR20140298A CR20140298A CR20140298A CR 20140298 A CR20140298 A CR 20140298A CR 20140298 A CR20140298 A CR 20140298A CR 20140298 A CR20140298 A CR 20140298A CR 20140298 A CR20140298 A CR 20140298A
- Authority
- CR
- Costa Rica
- Prior art keywords
- therapeutic use
- new therapeutic
- receiver antagonists
- antagonists
- receiver
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere al uso de un antagonista del receptor p75 o sus sales farmacéuticamente aceptables apra la preparación de un medicamento par auso en el tratamiento y/o prevención de vejiga sobreactiva.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306709.4A EP2606894A1 (en) | 2011-12-20 | 2011-12-20 | Novel therapeutic use of p75 receptor antagonists |
PCT/EP2012/076494 WO2013092918A1 (en) | 2011-12-20 | 2012-12-20 | Novel therapeutic use of p75 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20140298A true CR20140298A (es) | 2014-10-29 |
Family
ID=47429839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20140298A CR20140298A (es) | 2011-12-20 | 2014-06-19 | Nuevo uso terapéutico de antagonistas del receptor p75 |
Country Status (24)
Country | Link |
---|---|
US (2) | US20140296513A1 (es) |
EP (2) | EP2606894A1 (es) |
JP (2) | JP6275649B2 (es) |
KR (1) | KR20140103151A (es) |
CN (1) | CN104144688B (es) |
AR (1) | AR089344A1 (es) |
AU (2) | AU2012356922B2 (es) |
BR (1) | BR112014014933A2 (es) |
CA (1) | CA2859582A1 (es) |
CL (1) | CL2014001619A1 (es) |
CO (1) | CO6990740A2 (es) |
CR (1) | CR20140298A (es) |
DO (1) | DOP2014000137A (es) |
EA (1) | EA028616B1 (es) |
HK (1) | HK1198580A1 (es) |
IL (1) | IL233189A0 (es) |
MA (1) | MA35850B1 (es) |
MX (1) | MX2014007673A (es) |
PE (1) | PE20141854A1 (es) |
PH (1) | PH12014501390A1 (es) |
SG (1) | SG11201403390QA (es) |
TN (1) | TN2014000269A1 (es) |
UY (1) | UY34535A (es) |
WO (1) | WO2013092918A1 (es) |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3236243A1 (de) | 1982-09-30 | 1984-04-05 | Merck Patent Gmbh, 6100 Darmstadt | Schwefelhaltige indolderivate |
FR2744448B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
KR20000052691A (ko) | 1996-10-21 | 2000-08-25 | 스트라칸 그라함 | 뉴로트로핀 길항제 조성물 |
AU749271B2 (en) | 1997-07-01 | 2002-06-20 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
DE19826841A1 (de) | 1998-06-16 | 1999-12-23 | Merck Patent Gmbh | Arylalkanoylpyridazine |
GB9905010D0 (en) | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
CA2369945A1 (en) | 1999-04-06 | 2000-10-12 | James L. Kelley | Neurotrophic thio substituted pyrimidines |
US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
FR2803593B1 (fr) | 2000-01-06 | 2002-02-15 | Sanofi Synthelabo | Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant |
UA77526C2 (en) | 2002-06-07 | 2006-12-15 | Sanofi Aventis | Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy |
FR2862967B1 (fr) | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
FR2862968B1 (fr) | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
TW200615268A (en) | 2004-08-02 | 2006-05-16 | Osi Pharm Inc | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
US20070099900A1 (en) * | 2005-09-15 | 2007-05-03 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
AU2009221860A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes |
TWI443098B (zh) | 2008-03-24 | 2014-07-01 | Medivation Technologies Inc | 吡啶并〔3,4-b〕吲哚及使用方法 |
CN101284838B (zh) | 2008-06-06 | 2011-05-04 | 天津药物研究院 | 含噻吩并吡啶的哌嗪类衍生物、其制备方法和用途 |
FR2932481B1 (fr) | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique. |
FR2932482B1 (fr) | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
JP2010254641A (ja) * | 2009-04-28 | 2010-11-11 | Astellas Pharma Inc | アゾールカルボキサミド化合物又はその塩 |
FR2953836B1 (fr) | 2009-12-14 | 2012-03-16 | Sanofi Aventis | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
FR2953839A1 (fr) | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
-
2011
- 2011-12-20 EP EP11306709.4A patent/EP2606894A1/en not_active Withdrawn
-
2012
- 2012-12-20 AR ARP120104842A patent/AR089344A1/es unknown
- 2012-12-20 WO PCT/EP2012/076494 patent/WO2013092918A1/en active Application Filing
- 2012-12-20 BR BR112014014933A patent/BR112014014933A2/pt not_active IP Right Cessation
- 2012-12-20 AU AU2012356922A patent/AU2012356922B2/en not_active Ceased
- 2012-12-20 KR KR1020147019353A patent/KR20140103151A/ko not_active Application Discontinuation
- 2012-12-20 JP JP2014548035A patent/JP6275649B2/ja not_active Expired - Fee Related
- 2012-12-20 EP EP12806060.5A patent/EP2793889A1/en not_active Withdrawn
- 2012-12-20 CN CN201280070033.2A patent/CN104144688B/zh not_active Expired - Fee Related
- 2012-12-20 MX MX2014007673A patent/MX2014007673A/es unknown
- 2012-12-20 EA EA201491226A patent/EA028616B1/ru not_active IP Right Cessation
- 2012-12-20 CA CA2859582A patent/CA2859582A1/en not_active Abandoned
- 2012-12-20 SG SG11201403390QA patent/SG11201403390QA/en unknown
- 2012-12-20 UY UY0001034535A patent/UY34535A/es not_active Application Discontinuation
- 2012-12-20 PE PE2014001001A patent/PE20141854A1/es not_active Application Discontinuation
-
2014
- 2014-06-17 US US14/306,882 patent/US20140296513A1/en not_active Abandoned
- 2014-06-17 TN TNP2014000269A patent/TN2014000269A1/en unknown
- 2014-06-17 IL IL233189A patent/IL233189A0/en unknown
- 2014-06-17 DO DO2014000137A patent/DOP2014000137A/es unknown
- 2014-06-18 CL CL2014001619A patent/CL2014001619A1/es unknown
- 2014-06-18 PH PH12014501390A patent/PH12014501390A1/en unknown
- 2014-06-19 CR CR20140298A patent/CR20140298A/es unknown
- 2014-06-27 CO CO14139616A patent/CO6990740A2/es unknown
- 2014-07-07 MA MA37184A patent/MA35850B1/fr unknown
- 2014-12-01 HK HK14112081.9A patent/HK1198580A1/xx unknown
-
2016
- 2016-08-10 US US15/233,227 patent/US9763940B2/en not_active Expired - Fee Related
-
2017
- 2017-09-29 JP JP2017189265A patent/JP2018030865A/ja active Pending
- 2017-10-20 AU AU2017248550A patent/AU2017248550A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201400108A (es) | Compuestos de heterociclilo | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
MX2015002378A (es) | Composicion ansiolitica, formulacion y metodo de uso. | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
MD4539C1 (ro) | 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1 | |
ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
BR112012032282A2 (pt) | administração transdérmica de memantina | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
CO7131375A2 (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
CO6852025A2 (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
PH12016502353A1 (en) | Pharmaceutical composition | |
TW201613577A (en) | Pharmaceutical combinations | |
UY35209A (es) | Compuestos tricíclicos | |
CL2016000325A1 (es) | Antagonistas de vía para tratar trastornos del sueño por cambio de fase | |
UY35211A (es) | Compuestos tricíclicos | |
UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? | |
MY172809A (en) | Spirothienopyran-piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse | |
EA201291274A1 (ru) | Применение антагонистов аденозиновых рецепторов aдля лечения легочной гипертензии | |
CR20140298A (es) | Nuevo uso terapéutico de antagonistas del receptor p75 | |
UY35196A (es) | Nuevo uso de aclidinio | |
AR090605A1 (es) | Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer | |
MX358211B (es) | Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. | |
MX2014014813A (es) | Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño. | |
GT201500001A (es) | Composiciones líquidas orales pediátricas que contienen nepadutant |